Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
122.6 EUR | +1.83% | +3.68% | +55.92% |
Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.8 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.5 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+55.92% | 25.23B | - | ||
-4.66% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
-19.27% | 30.42B | B- | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
-9.14% | 11.95B | D+ | ||
+5.24% | 8.71B | B+ | ||
-8.42% | 8.12B | B- | ||
+2.29% | 7.72B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UCB Stock
- UNC Stock
- Ratings UCB